A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE

David Gibson (Inventor), AJ Bjourson (Inventor), Cathy McGeough (Inventor), Martin A Crockard (Inventor), John V. Lamont (Inventor)

Research output: Patent

Abstract

This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.
Original languageEnglish
Patent number WO2021234172A1
IPC C12Q1/6883
Priority date22/05/20
Filing date21/05/20
Publication statusPublished - 25 Nov 2021

Fingerprint

Dive into the research topics of 'A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE'. Together they form a unique fingerprint.

Cite this